CN110507655B - 化合物fg-4592在制备治疗甲状腺激素受体介导疾病的药物制剂中的应用 - Google Patents

化合物fg-4592在制备治疗甲状腺激素受体介导疾病的药物制剂中的应用 Download PDF

Info

Publication number
CN110507655B
CN110507655B CN201810492095.1A CN201810492095A CN110507655B CN 110507655 B CN110507655 B CN 110507655B CN 201810492095 A CN201810492095 A CN 201810492095A CN 110507655 B CN110507655 B CN 110507655B
Authority
CN
China
Prior art keywords
thr
thyroid hormone
agonist
hormone receptor
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810492095.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN110507655A (zh
Inventor
李勇
姚本强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiamen University
Original Assignee
Xiamen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiamen University filed Critical Xiamen University
Priority to CN201810492095.1A priority Critical patent/CN110507655B/zh
Priority to PCT/CN2019/087821 priority patent/WO2019223688A1/fr
Publication of CN110507655A publication Critical patent/CN110507655A/zh
Application granted granted Critical
Publication of CN110507655B publication Critical patent/CN110507655B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201810492095.1A 2018-05-22 2018-05-22 化合物fg-4592在制备治疗甲状腺激素受体介导疾病的药物制剂中的应用 Active CN110507655B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201810492095.1A CN110507655B (zh) 2018-05-22 2018-05-22 化合物fg-4592在制备治疗甲状腺激素受体介导疾病的药物制剂中的应用
PCT/CN2019/087821 WO2019223688A1 (fr) 2018-05-22 2019-05-21 Application du composé fg-4592 dans la préparation d'une préparation pharmaceutique pour le traitement de maladies médiées par le récepteur de l'hormone thyroïdienne

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810492095.1A CN110507655B (zh) 2018-05-22 2018-05-22 化合物fg-4592在制备治疗甲状腺激素受体介导疾病的药物制剂中的应用

Publications (2)

Publication Number Publication Date
CN110507655A CN110507655A (zh) 2019-11-29
CN110507655B true CN110507655B (zh) 2022-10-28

Family

ID=68617157

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810492095.1A Active CN110507655B (zh) 2018-05-22 2018-05-22 化合物fg-4592在制备治疗甲状腺激素受体介导疾病的药物制剂中的应用

Country Status (2)

Country Link
CN (1) CN110507655B (fr)
WO (1) WO2019223688A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2749719C1 (ru) * 2020-10-08 2021-06-16 Нестерук Владимир Викторович Препарат для лечения анемии, связанной с хроническим заболеванием почек, и способ его получения
CN112274512A (zh) * 2020-11-11 2021-01-29 浙江尖峰药业有限公司 罗沙司他在抑制急性酒精性脂肪肝药物中的应用
WO2024054996A1 (fr) * 2022-09-09 2024-03-14 Autobahn Therapeutics, Inc. Méthodes pour le traitement de la dépression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1644336T3 (pl) * 2003-06-06 2011-07-29 Fibrogen Inc Związki heteroarylowe zawierające azot i ich zastosowanie w zwiększaniu poziomu endogennej erytropoetyny
JP5390184B2 (ja) * 2005-06-06 2014-01-15 ファイブローゲン、インコーポレーテッド 貧血の改良された治療方法
CN104427980A (zh) * 2012-03-09 2015-03-18 菲布罗根有限公司 高胆固醇的治疗
CN104892509B (zh) * 2015-06-04 2018-03-09 苏州明锐医药科技有限公司 诺得司他的制备方法
CN106187888A (zh) * 2016-07-18 2016-12-07 江苏德源药业股份有限公司 Fg‑4592单晶及其制备方法
CN107468692A (zh) * 2017-08-18 2017-12-15 上海市第人民医院 HIF‑1α小分子激活剂FG‑4592在帕金森病中的应用
CN107854468A (zh) * 2017-11-29 2018-03-30 中国人民解放军第二军医大学 Fg‑4592在制备防护急性放射性骨髓损伤药物中的应用

Also Published As

Publication number Publication date
WO2019223688A1 (fr) 2019-11-28
CN110507655A (zh) 2019-11-29

Similar Documents

Publication Publication Date Title
CN110507655B (zh) 化合物fg-4592在制备治疗甲状腺激素受体介导疾病的药物制剂中的应用
Blad et al. Biological and pharmacological roles of HCA receptors
Amato et al. GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain
Shinohara et al. The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss
JP2022523376A (ja) レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途
US6172201B1 (en) Cellular receptor for HIV-1 Vpr essential for G2/M phase
CN101389651A (zh) 受体特异性肿瘤坏死因子相关的细胞凋亡诱导配体(trail)的突变体
JP2010046088A (ja) 新規なぺプチド類
Zhang et al. Trends in targeting Bcl-2 anti-apoptotic proteins for cancer treatment
Gessi et al. Glucocorticoids' pharmacology: past, present and future
JP2002500041A (ja) 炎症応答に関与するリゾ脂質受容体の同定
CN105744937A (zh) 高效糖皮质激素
Mazaleuskaya et al. Druggable prostanoid pathway
WO2001060370A1 (fr) Remedes contre les maladies induites par l'endotheline
Pan et al. Role of calmodulin in HIV-potentiated Fas-mediated apoptosis.
Chatterjee et al. Stimulation of heat shock protein 90 chaperone function through binding of a novobiocin analog KU-32
Tsuda et al. Inhibitory effect of M50054, a novel inhibitor of apoptosis, on anti-Fas-antibody-induced hepatitis and chemotherapy-induced alopecia
Wang et al. IL-33/ST2 antagonizes STING signal transduction via autophagy in response to acetaminophen-mediated toxicological immunity
Wang et al. A plant‐derived glucocorticoid receptor modulator with potency to attenuate the side effects of glucocorticoid therapy
Gomez-Sanchez et al. Aldosterone/Mineralocorticoid receptors and their renal effects: molecular biology and gene regulation
JP3603138B2 (ja) 細胞死抑制タンパク質
Murayama et al. Ryanodine receptor
US11103509B2 (en) Methods of treating pain and/or inflammatory disorders using lapatinib
JP2002526097A (ja) 新規なぺプチド類
Zhi et al. A novel TWIK2 channel inhibitor binds at the bottom of the selectivity filter and protects against LPS-induced experimental endotoxemia in vivo

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant